WO2002085932A3 - Constructs and methods for expression of recombinant hcv envelope proteins - Google Patents

Constructs and methods for expression of recombinant hcv envelope proteins Download PDF

Info

Publication number
WO2002085932A3
WO2002085932A3 PCT/BE2002/000062 BE0200062W WO02085932A3 WO 2002085932 A3 WO2002085932 A3 WO 2002085932A3 BE 0200062 W BE0200062 W BE 0200062W WO 02085932 A3 WO02085932 A3 WO 02085932A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv envelope
methods
expression
envelope proteins
constructs
Prior art date
Application number
PCT/BE2002/000062
Other languages
French (fr)
Other versions
WO2002085932A2 (en
Inventor
Erwin Sablon
Broekhoven Annie Van
Alfons Bosman
Erik Depla
Geert Deschamps
Original Assignee
Innogenetics Nv
Erwin Sablon
Broekhoven Annie Van
Alfons Bosman
Erik Depla
Geert Deschamps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv, Erwin Sablon, Broekhoven Annie Van, Alfons Bosman, Erik Depla, Geert Deschamps filed Critical Innogenetics Nv
Priority to MXPA03009626A priority Critical patent/MXPA03009626A/en
Priority to CA002443740A priority patent/CA2443740A1/en
Priority to NZ529019A priority patent/NZ529019A/en
Priority to BR0209033-3A priority patent/BR0209033A/en
Priority to AU2002308449A priority patent/AU2002308449B2/en
Priority to EP02764023A priority patent/EP1381671A2/en
Priority to APAP/P/2003/002886A priority patent/AP2003002886A0/en
Priority to JP2002583458A priority patent/JP2004536582A/en
Publication of WO2002085932A2 publication Critical patent/WO2002085932A2/en
Publication of WO2002085932A3 publication Critical patent/WO2002085932A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]

Abstract

The current invention relates to vectors and methods for efficient expression of HCV envelope proteins in eukaryotic cells. More particularly said vectors comprise the coding sequence for an avian lysozyme signal peptide or a functional equivalent thereof joined to a HCV envelope protein or a part thereof. Said avian lysozyme signal peptide is efficiently removed when the protein comprising said avian lysozyme signal peptide joined to a HCV envelope protein or a part thereof is expressed in a eukaryotic cell. Suitable eukaryotic cells include yeast cells such as Saccharomyces or Hansenula cells.
PCT/BE2002/000062 2001-04-24 2002-04-24 Constructs and methods for expression of recombinant hcv envelope proteins WO2002085932A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MXPA03009626A MXPA03009626A (en) 2001-04-24 2002-04-24 Constructs and methods for expression of recombinant hcv envelope proteins.
CA002443740A CA2443740A1 (en) 2001-04-24 2002-04-24 Constructs and methods for expression of recombinant hcv envelope proteins
NZ529019A NZ529019A (en) 2001-04-24 2002-04-24 Recombinant HCV envelope fusion proteins comprising an avian lysozyme leader peptide
BR0209033-3A BR0209033A (en) 2001-04-24 2002-04-24 Constructs and Methods for Expression of Recombinant Hcv Wrap Proteins
AU2002308449A AU2002308449B2 (en) 2001-04-24 2002-04-24 Constructs and methods for expression of recombinant hcv envelope proteins
EP02764023A EP1381671A2 (en) 2001-04-24 2002-04-24 Constructs and methods for expression of recombinant hcv envelope proteins
APAP/P/2003/002886A AP2003002886A0 (en) 2001-04-24 2002-04-24 Constructs and methods for expression of recombinant HCV envelope proteins
JP2002583458A JP2004536582A (en) 2002-04-24 2002-04-24 Constructs and methods for expression of recombinant HCV envelope proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01870088 2001-04-24
EP01870088.0 2001-04-24
US30560401P 2001-07-17 2001-07-17
US60/305,604 2001-07-17

Publications (2)

Publication Number Publication Date
WO2002085932A2 WO2002085932A2 (en) 2002-10-31
WO2002085932A3 true WO2002085932A3 (en) 2003-03-13

Family

ID=34072546

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/BE2002/000063 WO2002086100A2 (en) 2001-04-24 2002-04-24 Expression of core-glycosylated hcv envelope proteins in yeast
PCT/BE2002/000062 WO2002085932A2 (en) 2001-04-24 2002-04-24 Constructs and methods for expression of recombinant hcv envelope proteins
PCT/BE2002/000064 WO2002086101A2 (en) 2001-04-24 2002-04-24 Core-glycosylated hcv envelope proteins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/BE2002/000063 WO2002086100A2 (en) 2001-04-24 2002-04-24 Expression of core-glycosylated hcv envelope proteins in yeast

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/BE2002/000064 WO2002086101A2 (en) 2001-04-24 2002-04-24 Core-glycosylated hcv envelope proteins

Country Status (20)

Country Link
US (3) US7238356B2 (en)
EP (3) EP1414942A2 (en)
JP (2) JP4261195B2 (en)
KR (1) KR100950104B1 (en)
CN (1) CN1636050A (en)
AR (3) AR035869A1 (en)
AU (3) AU2002308449B2 (en)
BR (2) BR0209034A (en)
CA (3) CA2443781A1 (en)
CZ (1) CZ20032853A3 (en)
HU (1) HUP0303924A2 (en)
MX (2) MXPA03009626A (en)
NZ (2) NZ529324A (en)
OA (1) OA13092A (en)
PL (1) PL366621A1 (en)
RU (1) RU2274643C2 (en)
SK (1) SK13142003A3 (en)
WO (3) WO2002086100A2 (en)
YU (1) YU84103A (en)
ZA (3) ZA200308272B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
EP1414942A2 (en) * 2001-04-24 2004-05-06 Innogenetics N.V. Expression of core-glycosylated hcv envelope proteins in yeast
DE10143490C2 (en) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Recombinant MVA with the ability to express HCV structural antigens
CA2504711A1 (en) * 2002-11-08 2004-05-21 Innogenetics N.V. Hcv vaccine compositions comprising e1 and ns3 peptides
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP4371739B2 (en) * 2003-09-02 2009-11-25 株式会社東芝 Electronic device having serial ATA interface and power saving method of serial ATA bus
EP1602664A1 (en) * 2004-03-08 2005-12-07 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
EP1574517A1 (en) 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
JP4885476B2 (en) * 2004-05-21 2012-02-29 株式会社日本触媒 Method for introducing protein and / or peptide into cell
SG156652A1 (en) * 2004-10-18 2009-11-26 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis c infection
AU2011254055B2 (en) * 2004-10-18 2012-12-20 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20060234360A1 (en) * 2005-04-13 2006-10-19 Paola Branduardi Ascorbic acid production from D-glucose in yeast
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
PE20070796A1 (en) * 2005-10-24 2007-08-15 Wyeth Corp PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS
WO2007136865A2 (en) * 2006-05-19 2007-11-29 Glycofi, Inc Recombinant vectors
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
CN101563362B (en) * 2006-08-25 2015-02-11 麦克法兰布奈特医疗研究与公共健康研究所有限公司 Recombinant HCV E2 glycoprotein
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
DE102009044224A1 (en) * 2009-10-09 2011-04-28 PomBio Tech GmbH Starterzentrum der Universität des Saarlandes Campus Geb. A1-1 Method for production of HCV virus-like particles
UA118537C2 (en) 2010-12-22 2019-02-11 Байєр Інтеллектуал Проперті Гмбх Enhanced immune response in bovine species
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
WO2012152823A1 (en) 2011-05-09 2012-11-15 Ablynx Nv Method for the production of immunoglobulin single variable domains
US10155950B2 (en) * 2014-02-28 2018-12-18 Bayer Animal Health Gmbh Immunostimulatory plasmids
EP3374500A1 (en) * 2015-11-13 2018-09-19 Mammedov, Tarlan Production of in vivo n-deglycosylated recombinant proteins by co-expression with endo h
DK3184642T3 (en) * 2015-12-22 2019-08-12 Bisy E U yeast
WO2018055535A2 (en) 2016-09-21 2018-03-29 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288198A2 (en) * 1987-04-20 1988-10-26 Takeda Chemical Industries, Ltd. Production of Peptide
US5135854A (en) * 1987-10-29 1992-08-04 Zymogenetics, Inc. Methods of regulating protein glycosylation
WO1996004385A2 (en) * 1994-07-29 1996-02-15 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395395A (en) * 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
JP2791418B2 (en) * 1987-12-02 1998-08-27 株式会社ミドリ十字 Method for producing heterologous protein, recombinant DNA, transformant
NO177065C (en) * 1988-09-26 1995-07-12 Labofina Sa Process for the preparation of enzymatically active human lysozyme
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
WO1992001800A1 (en) * 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
HU227547B1 (en) 1991-06-24 2011-08-29 Novartis Vaccines & Diagnostic Hepatitis c virus (hcv) polypeptides
AU4659993A (en) 1992-07-07 1994-01-31 Merck & Co., Inc. Vaccine comprising mixed pres1+pres2+s and core particle
EP0979867A3 (en) 1993-11-04 2007-06-13 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
WO1998028429A1 (en) * 1996-12-20 1998-07-02 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
WO1999024466A2 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
EP1049790A1 (en) * 1998-01-23 2000-11-08 Novo Nordisk A/S Process for making desired polypeptides in yeast
PT1071955E (en) * 1998-04-17 2005-02-28 Innogenetics Nv IMMUNOLOGICAL DIAGNOSTIC IMPROVED ASSAYS USING REDUCING AGENTS
IL140217A0 (en) 1998-06-24 2002-02-10 Innogenetics Nv Particles of hcv envelope proteins: use for vaccination
CZ20021819A3 (en) 1999-10-27 2003-06-18 Innogenetics N. V. Oxidizing-reducing reversible HCV proteins with conformation similar to native proteins
MXPA02008886A (en) 2001-01-11 2003-04-25 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use.
EP1414942A2 (en) * 2001-04-24 2004-05-06 Innogenetics N.V. Expression of core-glycosylated hcv envelope proteins in yeast
JP2005516939A (en) 2001-12-18 2005-06-09 イノジェネティックス・ナムローゼ・フェンノートシャップ Purified hepatitis C virus coat protein for diagnostic and therapeutic uses
CA2504711A1 (en) * 2002-11-08 2004-05-21 Innogenetics N.V. Hcv vaccine compositions comprising e1 and ns3 peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288198A2 (en) * 1987-04-20 1988-10-26 Takeda Chemical Industries, Ltd. Production of Peptide
US5135854A (en) * 1987-10-29 1992-08-04 Zymogenetics, Inc. Methods of regulating protein glycosylation
WO1996004385A2 (en) * 1994-07-29 1996-02-15 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KURODA S ET AL: "HEPATITIS B VIRUS ENVELOPE L PROTEIN PARTICLES SYNTHESIS AND ASSEMBLY IN SACCHAROMYCES CEREVISIAE, PURIFICATION AND CHARACTERIZATION", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 267, no. 3, 25 January 1992 (1992-01-25), pages 1953 - 1961, XP002937464, ISSN: 0021-9258 *
KURODA SHUN'ICHI ET AL: "Saccharomyces cerevisiae can release hepatitis B virus surface antigen (HBsAg) particles into the medium by its secretory apparatus.", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 40, no. 2-3, 1993, pages 333 - 340, XP009000216, ISSN: 0175-7598 *
MUSTILLI ANNA CHIARA ET AL: "Comparison of secretion of a hepatitis C virus glycoprotein in Saccharomyces cerevisiae and Kluyveromyces lactis.", RESEARCH IN MICROBIOLOGY, vol. 150, no. 3, April 1999 (1999-04-01), pages 179 - 187, XP002220087, ISSN: 0923-2508 *

Also Published As

Publication number Publication date
ZA200308274B (en) 2005-01-24
PL366621A1 (en) 2005-02-07
KR100950104B1 (en) 2010-03-30
AU2002308449B2 (en) 2008-05-29
WO2002086100A2 (en) 2002-10-31
ZA200308277B (en) 2004-07-08
WO2002085932A2 (en) 2002-10-31
JP4261195B2 (en) 2009-04-30
BR0209033A (en) 2005-01-11
AU2002252856A1 (en) 2002-11-05
HUP0303924A2 (en) 2004-03-01
US20030108561A1 (en) 2003-06-12
ZA200308272B (en) 2005-01-24
AU2002257392B2 (en) 2007-05-10
RU2003130955A (en) 2005-04-20
WO2002086101A3 (en) 2004-02-19
US7238356B2 (en) 2007-07-03
JP4173741B2 (en) 2008-10-29
US20030211597A1 (en) 2003-11-13
AR035869A1 (en) 2004-07-21
CN1636050A (en) 2005-07-06
WO2002086100A3 (en) 2004-02-19
WO2002086101A2 (en) 2002-10-31
EP1381671A2 (en) 2004-01-21
SK13142003A3 (en) 2004-11-03
CA2443781A1 (en) 2002-10-31
YU84103A (en) 2006-05-25
RU2274643C2 (en) 2006-04-20
AR035868A1 (en) 2004-07-21
JP2004536052A (en) 2004-12-02
EP1414942A2 (en) 2004-05-06
CZ20032853A3 (en) 2004-08-18
MXPA03009626A (en) 2004-06-30
JP2004532029A (en) 2004-10-21
NZ529019A (en) 2004-05-28
US7048930B2 (en) 2006-05-23
CA2444006A1 (en) 2002-10-31
EP1417298A2 (en) 2004-05-12
AR035867A1 (en) 2004-07-21
MXPA03009632A (en) 2004-06-30
KR20030094359A (en) 2003-12-11
OA13092A (en) 2006-11-10
US20030152940A1 (en) 2003-08-14
CA2443740A1 (en) 2002-10-31
US7314925B2 (en) 2008-01-01
NZ529324A (en) 2005-08-26
BR0209034A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
WO2002085932A3 (en) Constructs and methods for expression of recombinant hcv envelope proteins
WO2003100021A3 (en) Methods and dna constructs for high yield production of polypeptides
EP1304382A3 (en) Production of peptides in plants as viral coat protein fusions
CA2089094A1 (en) Expression of recombinant polypeptides with improved purification
WO2002055717A3 (en) Enhanced secretion of a polypeptide by a microorganism
WO2003052055A3 (en) Egvii endoglucanase and nucleic acids encoding the same
WO2003052056A3 (en) Egviii endoglucanase and nucleic acids encoding the same
WO1998056927A3 (en) Nucleic acids encoding polypeptide having protease activity
WO2005033316A3 (en) Secretion of proteins from yeasts
WO2002036627A3 (en) Interferons, uses and compositions related thereto
ATE317443T1 (en) N-TERMINAL EXTENDED PROTEINS EXPRESSED IN YEAST
AP2003002886A0 (en) Constructs and methods for expression of recombinant HCV envelope proteins
WO2002040696A3 (en) Methods for large scale protein production in prokaryotes
WO2003100022A3 (en) Methods and dna constructs for high yield production of polypeptides
AU5776799A (en) Modified hcv peptide vaccines
EP1499349A4 (en) Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
DE69634757D1 (en) VECTOR FOR THE EXPRESSION OF N-TERMINAL EXTENDED PROTEINS IN HEF-CELLS
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
WO2022208554A3 (en) Constructs and methods for increased expression of polypeptides
WO2003095610A3 (en) Directed evolution method of generating enhanced folding polypeptide variants
DE69333304D1 (en) INCREASED PRODUCTION OF SECRETED PROTEINS BY RECOMBINANT EUKARYOTIC CELLS
WO2003035892A3 (en) Novel methods for introducing molecules into cells and vectors and compositions for use in such methods
WO2003014363A8 (en) Vector for site-specific integration of heterologous dna sequences into the rdn a sites of methylotrophic yeasts
WO2002048187A3 (en) Secretion signal peptides, their dna sequences, expression vectors for eukaryotic cells that can be produced with the same, and use thereof for biotechnological production of proteins
WO2002002771A3 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2443740

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2003/002886

Country of ref document: AP

Ref document number: 2002308449

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 529019

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/009626

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003/08277

Country of ref document: ZA

Ref document number: 200308277

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002583458

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002764023

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002764023

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 529019

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 529019

Country of ref document: NZ